Peptide-based vaccines are currently being tested for their ability to induce or augment
tumor antigen (Ag)-specific CD8+ T-cell responses in cancer patients. Here we report that …

Monitoring of CD8+ T‐cell responses in cancer patients during peptide vaccination is
essential to provide useful surrogate markers and to demonstrate vaccine efficacy. We have …

Successful immunotherapy with peptide vaccines depends on the in vivo generation of
sufficient numbers of anti-tumor T cells with appropriate phenotypic and functional …

Purpose: The progressive immune dysfunctions that occur in patients with advanced
melanoma make them unlikely to efficiently respond to cancer vaccines. A multicenter …

The identification of many tumor-associated epitopes as nonmutated “self” Ags led to the
hypothesis that the induction of large numbers of self/tumor Ag-specific T cells would be …

Successful induction of functional tumor-specific T cells by peptide vaccination in animal
models has resulted in many clinical trials to test this approach in advanced-stage …

ECOG 1696 was a Phase II multi‐center trial testing vaccination with melanoma peptides,
gp100, MART‐1 and tyrosinase delivered alone, with GM‐CSF, IFN‐α2b or both cytokines to …

Purpose: As compared with natural tumor peptide sequences, carefully selected analog
peptides may be more immunogenic and thus better suited for vaccination. However, T cells …

Cancer vaccines targeting CD8+ T cells have been successful in eliciting immunologic
responses but disappointing in inducing clinical responses. Strong evidence supports the …

The recent identification and molecular characterization of tumor-associated antigens
recognized by tumor-reactive CD8+ T lymphocytes has led to the development of antigen …